K
Kyle Concannon
Researcher at Harvard University
Publications - 9
Citations - 2123
Kyle Concannon is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 3, co-authored 3 publications receiving 1844 citations.
Papers
More filters
Journal ArticleDOI
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
Min Yu,Aditya Bardia,Ben S. Wittner,Shannon L. Stott,Malgorzata E. Smas,David T. Ting,Steven J. Isakoff,Jordan C. Ciciliano,Marissa N. Wells,Ajay Shah,Kyle Concannon,Maria C. Donaldson,Lecia V. Sequist,Elena F. Brachtel,Dennis C. Sgroi,José Baselga,Sridhar Ramaswamy,Mehmet Toner,Daniel A. Haber,Daniel A. Haber,Shyamala Maheswaran +20 more
TL;DR: A role for EMT in the blood-borne dissemination of human breast cancer is supported as both single cells and multicellular clusters, expressing known EMT regulators, including transforming growth factor (TGF)–β pathway components and the FOXC1 transcription factor.
Journal ArticleDOI
Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways
S. Michael Rothenberg,Kyle Concannon,Sarah Cullen,Gaylor Boulay,Alexa B. Turke,Anthony C. Faber,Elizabeth L. Lockerman,Miguel Rivera,Jeffrey A. Engelman,Shyamala Maheswaran,Daniel A. Haber +10 more
TL;DR: Observations point to a physiological feedback mechanism that attenuates oncogene addiction-mediated cell death associated with the withdrawal of growth factor signaling and may therefore contribute to the development of resistance.
Journal ArticleDOI
Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control.
TL;DR: In this paper , the molecular consequences of targeted DNA-damage response inhibition, from tumor cell death to increased engagement of the anti-tumor immune response, are discussed and mechanistic and clinical rationale for pairing targeted DDRis with immunotherapy for enhanced tumor control.
Proceedings ArticleDOI
Abstract A75: Circulating tumor cells in human breast cancer exhibit dynamic changes in epithelial and mesenchymal composition
Min Yu,Aditya Bardia,Ben S. Wittner,Shannon L. Stott,Malgorzata E. Smas,David T. Ting,Steven J. Isakoff,Jordan C. Ciciliano,Marissa N. Wells,Ajay Shah,Kyle Concannon,Maria C. Donaldson,Lecia V. Sequist,Elena F. Brachtel,Dennis C. Sgroi,José Baselga,Sridhar Ramaswamy,Mehmet Toner,Daniel A. Haber,Shyamala Maheswaran +19 more
TL;DR: Analysis of treatment responses in 10 patients suggested an association of mesenchymal CTCs with disease progression, and RNA sequencing of CTC clusters identified EMT-related signatures, including FOXC1, a known transcriptional regulator of EMT.
Journal ArticleDOI
MA01.03 Exploiting DNA Methylation for Classification of SCLC Subtypes from Liquid Biopsies Using a Robust Machine Learning Approach
Simon Heeke,C. Gay,Marcos R. Estecio,Allison C. Stewart,Hai T. Tran,Bo Zhang,X. Tang,Maria Gabriela Raso,Kyle Concannon,L. D. de Sousa,W. Lewis,Kazuki Kondo,Monique B. Nilsson,Yongchang Xi,Li-Rong Diao,Qi Wang,J Zhang,J. Wang,Ignacio I. Wistuba,Lauren Averett Byers,John V. Heymach +20 more
TL;DR: In this article , Gay CM et al. identified four major distinct subgroups of small cell lung cancer (SCLC): ASCL1, NEUROD, POU2F3 and inflamed phenotype.